Channelpedia

PubMed 26172285


Referenced in Channelpedia wiki pages of: none

Automatically associated channels: TRP , TRPM , TRPM4



Title: Sur1-Trpm4 Cation Channel Expression in Human Cerebral Infarcts.

Authors: Rupal I Mehta, Cigdem Tosun, Svetlana Ivanova, Natalia Tsymbalyuk, Bolanle M Famakin, Min Seong Kwon, Rudy J Castellani, Volodymyr Gerzanich, J Marc Simard

Journal, date & volume: J. Neuropathol. Exp. Neurol., 2015 Aug , 74, 835-49

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/26172285


Abstract
The nonselective monovalent cation channel transient receptor potential melastatin 4 (Trpm4) is transcriptionally upregulated in neural and vascular cells in animal models of brain infarction. It associates with sulfonylurea receptor 1 (Sur1) to form Sur1-Trpm4 channels, which have critical roles in cytotoxic edema, cell death, blood-brain barrier breakdown, and vasogenic edema. We examined Trpm4 expression in postmortem brain specimens from 15 patients who died within the first 31 days of the onset of focal cerebral ischemia. We found increased Trpm4 protein expression in all cases using immunohistochemistry; transcriptional upregulation was confirmed using in situ hybridization of Trpm4 messenger RNA. Transient receptor potential melastatin 4 colocalized and coassociated with Sur1 within ischemic endothelial cells and neurons. Coexpression of Sur1 and Trpm4 in necrotic endothelial cells was also associated with vasogenic edema indicated by upregulated perivascular tumor necrosis factor, extravasation of serum immunoglobulin G, and associated inflammation. Upregulated Trpm4 protein was present up to 1 month after the onset of cerebral ischemia. In a rat model of middle cerebral artery occlusion stroke, pharmacologic channel blockade by glibenclamide, a selective inhibitor of sulfonylurea receptor, mitigated perivascular tumor necrosis factor labeling. Thus, upregulated Sur1-Trpm4 channels and associated blood-brain barrier disruption and cerebral edema suggest that pharmacologic targeting of this channel may represent a promising therapeutic strategy for the clinical management of patients with cerebral ischemia.